Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
12 08 2020
Historique:
revised: 28 02 2020
received: 18 10 2019
accepted: 24 07 2020
entrez: 18 8 2020
pubmed: 18 8 2020
medline: 24 6 2021
Statut: ppublish

Résumé

Disruption of the intestinal microbiota occurs frequently in allogeneic hematopoietic cell transplantation (allo-HCT) recipients and predisposes them to development of graft-versus-host disease (GvHD). In a prospective, single-center, single-arm study, we investigated the effect of donor fecal microbiota transplantation (FMT) on symptoms of steroid-refractory or steroid-dependent, acute or late-onset acute intestinal GvHD in 15 individuals who had undergone allo-HCT. Study participants received a fecal suspension from an unrelated healthy donor via nasoduodenal infusion. Donor FMT was well tolerated, and infection-related adverse events did not seem to be related to the FMT procedure. In 10 of 15 study participants, a complete clinical response was observed within 1 month after FMT, without additional interventions to alleviate GvHD symptoms. This response was accompanied by an increase in gut microbial α-diversity, a partial engraftment of donor bacterial species, and increased abundance of butyrate-producing bacteria, including Clostridiales and

Identifiants

pubmed: 32801142
pii: 12/556/eaaz8926
doi: 10.1126/scitranslmed.aaz8926
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Yannouck F van Lier (YF)

Department of Hematology, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.
Department of Experimental Immunology, Amsterdam Institute for Infection and Immunity (AII), Cancer Center Amsterdam, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.

Mark Davids (M)

Department of Vascular Medicine, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.

Nienke J E Haverkate (NJE)

Department of Experimental Immunology, Amsterdam Institute for Infection and Immunity (AII), Cancer Center Amsterdam, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.

Pieter F de Groot (PF)

Department of Vascular Medicine, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.

Marjolein L Donker (ML)

Department of Hematology, Amsterdam UMC, location VUMC, 1081 HV Amsterdam, Netherlands.

Ellen Meijer (E)

Department of Hematology, Amsterdam UMC, location VUMC, 1081 HV Amsterdam, Netherlands.

Floor C J I Heubel-Moenen (FCJI)

Department of Hematology, Maastricht University Medical Center, 6229 HX Maastricht, Netherlands.

Erfan Nur (E)

Department of Hematology, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.

Sacha S Zeerleder (SS)

Department of Hematology, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.
Department of Immunopathology, Sanquin Research, 1066 CX Amsterdam, Netherlands.
Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Department for BioMedical Research, University of Bern, 3010 Bern, Switzerland.

Max Nieuwdorp (M)

Department of Vascular Medicine, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.
Diabetes Center, Department of Internal Medicine, Amsterdam UMC, location VUMC, 1081 HV Amsterdam, Netherlands.
Institute for Cardiovascular Research (ICaR), Amsterdam UMC, location VUMC, 1081 HV Amsterdam, Netherlands.
Wallenberg Laboratory, University of Gothenburg, SE-413 45 Goteborg, Sweden.

Bianca Blom (B)

Department of Experimental Immunology, Amsterdam Institute for Infection and Immunity (AII), Cancer Center Amsterdam, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.

Mette D Hazenberg (MD)

Department of Hematology, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands. m.d.hazenberg@amsterdamumc.nl.
Department of Experimental Immunology, Amsterdam Institute for Infection and Immunity (AII), Cancer Center Amsterdam, Amsterdam UMC, location AMC, 1105 AZ Amsterdam, Netherlands.
Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH